Agreement - September 25, 2017
Promore Pharma in agreement with APL
Promore Pharma announces that a manufacturing agreement has been entered with APL for the production of investigational medicinal product for its LL-37 Phase IIb trial in patients with hard-to-heal leg ulcers. The trial will be conducted in Europe with a planned start for patient enrolment in 2018. VLU constitutes the largest category of all chronic, […]
Clinical Trials - January 4, 2017
Promore Pharma enters Phase III clinical collaboration
Promore Pharma and Cellastra, a clinical stage developer of pharmaceutical assets, has announced the signing of a term sheet, towards a strategic collaboration for the Phase III clinical development of PXL01 and subsequent registration and marketing in the US and Canada. “This co-development initiative for PXL01 in the US market is pivotal to our strategic […]
Collaboration - August 17, 2016
Promore collaborates with British Technomark
Technomark Life Sciences and Promore Pharma announced earlier this summer a strategic collaboration on the end-stage development of PXL01 for European registration and marketing, a product opportunity for prevention of post-surgical adhesions after hand-surgery, which has completed Phase II trials. The two companies will collaborate on the Phase III clinical development of PXL01, a novel […]
